Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a targeted therapy in two indications: in combination with...
Consolidated sales revenue of €4.876 billion, up 9.8% (+6.6% at CERi), driven by strong growth in international sales Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at ...
Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its...
Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and...
Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind,...
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier's antibody center of...
Servier and Treventis announce strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases. The collaboration covers a large drug discovery program...
MONTREAL, Oct. 20 /CNW/ - New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients...
ISTANBUL, Turkey, Sept. 15 /CNW/ - Further evidence of the superior antidepressant efficacy of Valdoxan(R)/Thymanax(R) (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs)...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.